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Objectives. The aim of this study was to determine whether the
combination of lipid-lowering therapy and vitamin E supplemen-
tation improves peripheral endothelial function and whether it is
more effective than lipid-lowering therapy alone.
Background. Endothelium-dependent vasodilation is impaired
in coronary and peripheral arteries of patients with hypercholes-
terolemia. Coronary endothelial function has been shown to
improve under lipid-lowering and antioxidant therapy, but the
effect of additive vitamin E supplementation in the brachial artery
is unknown.
Methods. Seven patients with hypercholesterolemia (mean 6
SD; age 51 6 10 yr) were studied. Endothelium-dependent,
flow-mediated dilation (FMD) and endothelium-independent
nitroglycerin-induced dilation (NMD) were assessed in the bra-
chial artery using high resolution ultrasound 1) at baseline (BL I),
2) after 8 weeks of simvastatin (20 mg) and vitamin E (300 IU)
therapy (Comb I), 3) after withdrawal of vitamin E for 4 weeks
(Statin), 4) after therapy as in #2 for 4 weeks (Comb II) and 5)
after withdrawal of both drugs for 4 weeks (BL II).
Results. Combined simvastatin and vitamin E therapy reduced
total cholesterol (Comb I vs. BL I: 276 6 22 vs. 190 6 14 mg/dl,
p < 0.0001) and low-density lipoprotein (LDL)-C (197 6 22 vs.
106 6 22 mg/dl, p < 0.00001), augmented alpha tocopherol levels
normalized to LDL (12.2 6 4.1 vs. 4.9 6 0.9 mg alpha-T/100 mg%
LDL-C, p < 0.01) and resulted in significant improvements in
FMD (16.4 6 4.7 vs. 4.9 6 2.5%, p < 0.001) as well as NMD
(17.9 6 4.3 vs. 11.2 6 2.8%, p < 0.01). The ratio of FMD to NMD
(0.92 6 0.17 vs. 0.46 6 0.24%, p < 0.05) also increased under
combination therapy, indicating a greater improvement of FMD
than that of NMD. After withdrawal of vitamin E, both FMD
(Comb I vs. Statin: 16.4 6 4.7 vs. 7.9 6 4.7%, p < 0.01) and NMD
(17.9 6 4.3 vs. 10.9 6 4.5%, p < 0.05) decreased significantly such
that simvastatin alone only tended to improve FMD and did not
change NMD. Results under combination therapy (Comb II vs. BL
II) were reproducible.
Conclusions. Combined vitamin E and simvastatin therapy
leads to an improvement of FMD and NMD in the brachial artery
of patients with hypercholesterolemia. The improvement of FMD
is more pronounced after combination therapy than after lipid-
lowering therapy alone, similar to previous findings in the coro-
nary circulation.
(J Am Coll Cardiol 1998;32:711–6)
©1998 by the American College of Cardiology
Hypercholesterolemia as well as low plasma concentrations of
vitamins E and C are associated with a high incidence of
cardiovascular disease (1–5). Epidemiologic studies have
shown that high intake of vitamin E is associated with a lower
risk of coronary heart disease in men and women (6,7).
Lowering the levels of total and low-density lipoprotein (LDL)
cholesterol in patients with coronary artery disease resulted in
a decrease in cardiac events even in patients with average
serum cholesterol levels (8–12).
Oxidative modification of LDL is assumed to play a key role
in the pathogenesis of atherosclerosis (13–15). Oxidized LDL
promotes foam cell formation (16,17), stimulates monocyte
adhesion (18,19) and is cytotoxic to vascular cells (20). More-
over, in the presence of oxidized LDL the G protein-
dependent stimulation of nitric oxide release is interrupted
(21,22) and the physiologic action of nitric oxide is directly
blocked by lipid peroxidation products (23).
Endothelium-dependent vasodilation, largely mediated by
nitric oxide (24), is impaired in coronary and peripheral
arteries of patients with hypercholesterolemia and coronary
artery disease (25–27) and can partly be restored by lipid-
lowering therapy (28–33). In coronary arteries of patients with
mild hypercholesterolemia the improvement in endothelium-
dependent vasodilator response to acetylcholine was more
pronounced after a combined lipid lowering (lovastatin) and
antioxidant therapy (probucol) (34) than after LDL-lowering
therapy or dietary means alone.
Although the oral intake of vitamin E, the main lipid-
soluble antioxidant in human plasma proteins and lipoproteins,
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restored endothelium-dependent vasodilation in cholesterol-
fed rabbits (35,36), it failed to improve endothelial function in
the human forearm microvasculature of patients with hyper-
cholesterolemia (37).
The present study was performed to determine whether the
combination of simvastatin therapy and vitamin E supplemen-
tation improves endothelial function of the brachial artery and
whether it is more effective than lipid-lowering therapy alone.
Methods
Patients. Seven patients (mean 6 SD, age 51 6 10 yr,
range 36 to 64) with total serum cholesterol levels $250 mg/dl
and LDL-C $150 mg/dl were enrolled in the study. All patients
kept a diet for at least 6 months (American Heart Association
Step I) but none of them took lipid-lowering or antioxidative
drugs prior to this study. Three patients had angiographic
evidence of coronary artery disease. One patient had mild
mitral and aortic regurgitation. In five patients hypercholester-
olemia was the only cardiovascular risk factor. In two patients
borderline hypertension was also present. All patients were
nonsmokers.
Assessment of FMD. In all subjects flow-mediated
endothelium-dependent vasodilation (FMD) following reac-
tive hyperemia and endothelium-independent nitroglycerin
(NTG)-induced vasodilation (NMD) were examined in the
brachial artery. Ultrasound measurements were performed
according to the method described by Celermajer et al. (26).
Using high resolution ultrasound (Acuson 128XP/10, Moun-
tain View, CA, with a 7.0 MHz linear array transducer),
diameter measurements of the right brachial artery were taken
at rest after lying quietly for at least 10 min, after cuff deflation
completing suprasystolic compression (200 mm Hg for 4.5 min)
of the right upper arm and after sublingual application of
0.8 mg NTG. Scans were taken of the brachial artery proximal
to the bifurcation of the radial and the ulnar artery by the
ultrasound operator (R.K.) who was working at a different
department and blinded to the subjects’ diagnoses and therapy
sequence. After optimal transducer positioning, the arm was
kept in the same position and the skin was marked. Lumen
diameters were measured from one media-adventitia interface
to the other for at least 3 times at baseline and every 30
seconds following reactive hyperemia and after administration
of NTG. The maximum FMD and NMD diameters were taken
as the average of the three consecutive maximum diameter
measurements following hyperemia and NTG, respectively.
Vasodilation was then calculated as the percent change in
diameter compared to baseline. Measurements were per-
formed at the end of five consecutive periods: 1) at baseline
(BL I), 2) after 8 weeks of a combined therapy with simvastatin
and vitamin E to achieve an LDL lowering of at least 20%
(Comb I), 3) after withdrawal of vitamin E (300 IU) for 4
weeks (Statin), 4) during a second combined drug period as in
#2 (Comb II), and 5) after withdrawal of both drugs for 4
weeks (BL II).
Assessment of hyperemic blood flow. To verify that supra-
systolic compression of the brachial artery caused adequate
increases in blood flow, flow velocity was measured at rest and
within 15 s after cuff deflation. Blood flow was calculated by
multiplying the velocity time integral by the heart rate and the
vessel cross-sectional area (3.14 3 D2/4.) Reactive hyperemia
was then calculated as percent change in flow during hyper-
emia compared to baseline. For comparison, blood flow was
also assessed 2 min after NTG administration.
Alpha-tocopherol measurements in human plasma sam-
ples. The neutral lipid fraction (200 ml) including alpha-
tocopherol, the most active form of vitamin E, was extracted in
a basic extraction system consisting of 200 ml ethanol, 200 ml
H2O and 200 ml hexane. The upper organic layer (20/ml)
containing alpha-tocopherol was analyzed by high-performance
liquid chromatography using an ExSil 100 20 3 0.46 cm silica
column (mobile phase: hexane/1% ethanol, 1 ml/min) and
fluorescence detection (Hitachi, E: 295nm/Em: 390nm) (38).
Quantitation was performed by peak area comparison with
external alpha-tocopherol standards of known concentrations.
The alpha-tocopherol serum level was then normalized to
LDL-C, as there is evidence that the vitamin E content in
LDL-C and not in the whole plasma correlates with measures
of lipid peroxidation (39) and with the susceptibility of LDL-C
to oxidation (40).
Determination of lipids and lipoproteins. Cholesterol and
triglycerides were measured enzymatically using assay kits
from Boehringer Mannheim (Mannheim, Germany). High-
density lipoprotein-C was measured from the supernatant after
precipitation with polyethylene glycol (Reagent A from Im-
muno A.G., Vienna, Austria). LDL-C was calculated according
to the Friedewald equation.
Statistical analysis. Results are expressed as mean 6 SD.
Differences between groups were analyzed using one factor
analysis of variance for repeated measures followed by Schef-
fe’s test. Post hoc paired t tests on longitudinal changes from
baseline were used to compare the improvements of FMD and
NMD after different therapies. The effects of cholesterol,
LDL-C, alpha-tocopherol, alpha-tocopherol/LDL, triglycer-
ides and baseline diameter on FMD or NMD were performed
with linear regression. Interactions between FMD or NMD
and lipid serum levels and alpha-tocopherol serum levels were
assessed using multiple stepwise regression analysis. Differ-
ences were considered significant at p , 0.05.
Abbreviations and Acronyms
BL 5 baseline
Comb 5 combined therapy
FMD 5 flow-mediated vasodilation
LDL-C 5 low-density lipoprotein-cholesterol
NMD 5 nitroglycerin-induced vasodilation
NTG 5 nitroglycerin
Statin 5 simvastatin therapy
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Results
Lipid and alpha-tocopherol serum levels. In all patients
simvastatin therapy (20 mg) led to a lowering of LDL-C of at
least 20%. Oral intake of 300 IU vitamin E did not lead to
significant increases in alpha-tocopherol serum levels. How-
ever, when the alpha-tocopherol serum level was normalized to
LDL-C, a significant increase was noted under combined
vitamin E and simvastatin medication compared to baseline
(Table 1).
Vasodilation and blood flow responses. As there were no
differences in the baseline diameters and increases in blood
flow during reactive hyperemia, the stimulus for FMD can be
assumed as being similar at the end of all five study phases
(Table 2). Combined lipid-lowering and vitamin E therapy
reproducibly resulted in a significant improvement of FMD
(Comb I vs. BL I: 16.4 6 4.7 vs. 4.9 6 2.5%, p , 0.001 and
Comb II vs. BL II; 15.3 6 4.2 vs. 3.7 6 3.9%, p , 0.001) (Fig.
1, 2). After withdrawal of vitamin E for 4 weeks, FMD
decreased significantly (Comb I and Comb II vs. Statin: 16.4 6
4.7 and 15.3 6 4.2 vs. 7.9 6 4.7%, p , 0.05) such that
simvastatin alone only tended to improve FMD and did not
change NMD (Table 2).
Similar although lesser improvement under combination
therapy was found for endothelium-independent vasodilation
(Fig. 3). NMD was augmented after combined lipid-lowering
and vitamin E therapy compared to baseline as well as
simvastatin therapy alone (Comb I vs. BL I and Statin: 17.9 6
4.3 vs. 11.2 6 2.8 and 10.9 6 4.5%, p , 0.01 and Comb II vs.
BL II and Statin: 16.3 6 6 5.1 vs. 11.5 6 2.7 and 10.9 6 4.5%,
p , 0.05). Blood flow after the application of NTG was similar
at the end of all periods (BL I 100 6 39, Comb I 87 6 30, Statin
106 6 30, Comb II 99 6 41, BL II 99 6 28 ml/min) and was
also similar to blood flow at baseline (BL I 123 6 61, Comb I
93 6 40, Statin 123 6 67, Comb II 115 6 37, BL II 106 6
28 ml/min).
Improvement of the FMD/NMD ratio was observed under
Table 1. Lipid and Alpha-Tocopherol Serum Levels
BL I Comb I Statin Comb II BL II p
Cholesterol (mg/dl) 276 6 22 190 6 14 210 6 36 201 6 19 294 6 37 BL I, II vs. Comb I ,0.0001 and vs.
(255–320) (176–218) (165–273) (171–222) (244–328) Comb II ,0.001 and vs. Statin
,0.01
LDL-C (mg/dl) 197 6 22 106 6 22 123 6 24 107 6 22 202 6 27 BL I, II vs. Comb I, II ,0.00001
(172–233) (75–145) (95–165) (69–137) (166–239) and vs. Statin ,0.0001
HDL-C (mg/dl) 39 6 7 40 6 9 42 6 10 40 6 6 46 6 8 NS
(30–47) (26–52) (27–57) (32–48) (38–55)
Triglycerides (mg/dl) 212 6 58 212 6 62 229 6 128 271 6 56 195 6 40 NS
(137–285) (148–313) (79–432) (213–350) (168–254)
Alpha-tocopherol (mg/ml) 9.6 6 3.0 11.8 6 2.6 8.6 6 2.2 13.3 6 2.9 10.6 6 5.4 NS
(7.0–15.0) (7.5–15.3) (6.8–11.0) (7.4–15.7) (6.9–18.6)
Alpha-tocopherol/LDL 4.9 6 0.9 12.2 6 4.1 7.0 6 1.0 12.7 6 4.0 5.8 6 2.2 Comb I, II vs. BL I ,0.01; Comb II
(mg/100 mg% LDL-C) (4.0–6.0) (9.0–20.0) (6.0–8.0) (7.0–20.0) (4.0–9.0) vs. BL II ,0.05
HDL-C 5 high-density lipoprotein-cholesterol.
Table 2. Vasodilation and Blood Flow Responses
BL I Comb I Statin Comb II BL II p
Baseline diameter (mm) 4.6 6 0.4 4.6 6 0.6 5.0 6 0.4 4.8 6 0.4 4.8 6 0.3 NS
(4.2–5.4) (4.1–5.8) (4.5–5.8) (4.3–5.5) (4.4–5.2)
Hyperemia diameter (mm) 4.9 6 0.4 5.4 6 0.5 5.4 6 0.2 5.5 6 0.3 5.0 6 0.3 NS
(4.4–5.6) (4.9–6.4) (5.2–5.8) (5.0–5.9) (4.6–5.3)
Hyperemia (%) 279 6 141 338 6 172 338 6 218 256 6 157 302 6 104 NS
(114–450) (187–683) (127–700) (100–500) (154–463)
FMD (%) 4.9 6 2.5 16.4 6 4.7 7.9 6 4.7 15.3 6 4.2 3.7 6 3.9 Comb I, II vs. BL II and Comb I vs.
(2.2–9.6) (9.7–23.3) (0.0–15.6) (7.8–21.7) (0.0–12.1) BL I ,0.0001, Comb II vs. BL I
,0.001, Comb I, II vs. Statin
,0.05
NMD diameter (mm) 5.2 6 0.3 5.5 6 0.6 5.6 6 0.3 5.5 6 0.3 5.4 6 0.3 NS
(4.8–5.8) (5.0–6.7) (5.3–6.3) (5.1–6.0) (5.0–5.7)
NMD (%) 11.2 6 2.8 17.9 6 4.3 10.9 6 4.5 16.3 6 5.1 11.5 6 2.7 Comb I vs. BL I, II, Statin ,0.01,
(7.4–14.3) (11.1–22.7) (6.0–20.0) (9.1–24.6) (7.7–14.6) Comb II vs. BL I, II, Statin
,0.05
FMD/NMD ratio (%) 0.46 6 0.24 0.92 6 0.17 0.71 6 0.34 0.95 6 0.13 0.29 6 0.26 Comb I, II vs. BL II ,0.01 and vs.
(0.17–0.82) (0.65–1.12) (0.00–1.00) (0.80–1.20) (0.00–0.80) BL I ,0.05, Statin vs. BL II
,0.05
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both combination therapy (Comb I vs. BL I: 0.92 6 0.17 vs.
0.46 6 0.24%, p , 0.05 and Comb II vs. BL II: 0.95 6 0.31 vs.
0.29 6 0.26%, p , 0.01) and lipid-lowering therapy alone
(Statin vs. BL II: 0.71 6 0.34 vs. 0.29 6 0.26%, p , 0.05).
Post hoc paired t tests on longitudinal changes from base-
line revealed a greater improvement of FMD (Comb I vs.
Statin, p 5 0.004; Comb II vs. Statin, p 5 0.0001) and NMD
(Comb I vs. Statin, p 5 0.007; Comb II vs. Statin, p 5 0.01)
after combined lipid-lowering and vitamin E therapy compared
to lipid-lowering therapy alone (Table 3).
Univariate analysis over all periods revealed significant
correlations between FMD values and total cholesterol serum
levels (r 5 20.67, p 5 0.0001), LDL-C levels (r 5 20.64, p 5
0.0001), alpha-tocopherol/LDL (r 5 0.59, p 5 0.001) and
baseline diameter (r 5 20.49, p 5 0.002). NMD values were
significantly correlated to baseline diameters (r 5 20.59, p 5
0.0002), total cholesterol (r 5 20.43, p 5 0.02), LDL-C (r 5
20.39, p 5 0.02) and alpha-tocopherol/LDL (r 5 0.44, p 5
0.02).
On multiple stepwise regression analysis over all periods,
significant correlations were found between FMD values and
total cholesterol levels (r 5 20.62, p 5 0.004) (which was the
first variable to be entered), alpha-tocopherol levels (r 5 0.40,
p 5 0.03) and baseline diameter (r 5 20.45, 0.003). NMD
values were independently correlated with LDL-C levels (r 5
20.50, p 5 0.03) and baseline diameters (r 5 20.47, p 5 0.02).
Discussion
The present study demonstrates that endothelium-
dependent FMD in the brachial artery of patients with hyper-
cholesterolemia can be improved by a combination of lipid-
lowering therapy and vitamin E supplementation. This is, to
the best of our knowledge, the first study revealing a beneficial
effect of vitamin E on vasoreactivity in the brachial artery of
hypercholesterolemic men under lipid-lowering therapy. This
therapy also resulted in an improvement of endothelium-
independent, nitroglycerin-induced vasodilation, albeit to a
lesser extent than FMD. Our data further suggest that the
combination of lipid-lowering therapy with vitamin E supple-
mentation is more effective in restoring endothelial function in
hypercholesterolemic patients than lipid-lowering therapy
alone.
Endothelium-dependent dilation in hypercholesterolemia.
Endothelial function of peripheral arteries is increasingly used
to assess short-term effects of therapeutic interventions. Im-
provement of endothelial function in the forearm vasculature
of patients with hypercholesterolemia was observed within 1
month of simvastatin therapy (32) and after a single session ofFigure 2. Nitroglycerin-induced dilation (NMD) values of seven pa-
tients with hypercholesterolemia at baseline (BL I, II) after combined
lipid-lowering and antioxidant therapy (Comb I, II) and after single
lipid-lowering therapy (Statin).
Figure 3. Mean values of flow-mediated vasodilation (FMD), plasma
cholesterol, LDL-cholesterol and alpha-tocopherol/LDL at baseline
(BL I, II) after combined lipid-lowering and antioxidant therapy
(Comb I, II) and after single lipid-lowering therapy (Statin).
Table 3. Longitudinal Changes of FMD and NMD From Baseline
Under Combined Vitamin E/Simvastatin Therapy vs. Simvastatin
Therapy Alone
Comb I
vs Statin
Comb II
vs Statin
FMD
Mean difference 6 SE 8.6 6 1.9 7.4 6 0.8
Paired t 4.5 8.8
p (two tail) 0.004 0.0001
NMD
Mean difference 6 SE 7.0 6 1.8 5.4 6 1.6
Paired t 4 3.4
p (two tail) 0.007 0.01
Figure 1. Flow-mediated vasodilation (FMD) values of seven patients
with hypercholesterolemia at baseline (BL I, II) after combined
lipid-lowering and antioxidant therapy (Comb I, II) and after single
lipid-lowering therapy (Statin).
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LDL apheresis (33). In the latter study, the authors suggested
that total LDL and/or oxidized LDL may directly impair
endothelial function on the basis of a close inverse correlation
between oxidized LDL and acetylcholine-induced vasodilation
and nitrate/nitrite production (33). In coronary arteries of
patients with mild hypercholesterolemia, improvement of en-
dothelial function was more pronounced under combination
therapy of lovastatin and probucol than under lovastatin alone
(34). Our study extends these findings by showing that a
combined lipid-lowering and antioxidant therapy is highly
effective also in the brachial artery and that vitamin E intake in
addition to lipid-lowering therapy leads to further improve-
ment in endothelial function. With regard to the effects of
antioxidant vitamins alone, conflicting results have been ob-
tained. Gilligan et al. (37) did not find a beneficial effect of
vitamins C and E on endothelial function in forearm vessels of
patients with hypercholesterolemia using strain gauge plethys-
mography. Levine et al. (41) demonstrated an acute improve-
ment of endothelial function with the water-soluble antioxi-
dant vitamin C given to patients with cardiovascular disease
within 2 h.
Endothelium-independent dilation in hypercholesterol-
emia. An unexpected finding in this study was that lipid-
lowering and antioxidant (vitamin E) therapy also improved
NMD in the brachial artery. This is in contrast to the findings
of Anderson et al. (34) in coronary arteries, who used probucol
as an antioxidant together with lovastatin. Other possible
explanations for the discrepancy between that study and ours
include higher mean cholesterol (276 6 22 vs. 217 6 32 mg/dl)
and LDL-C serum levels (276 6 22 vs. 145 6 37 mg/dl) in our
study and the fact that different arteries were investigated.
In coronary arteries of hypertensive patients (42) and in the
brachial artery of patients with coronary disease (41), the
water-soluble antioxidant vitamin C failed to improve
endothelium-independent vasodilation. However, as the pri-
mary antioxidant mechanisms of vitamin C and E are distinct,
different effects of these substances on the vascular wall cannot
be excluded (43).
The mechanism of improved endothelium-independent va-
sodilation in the brachial artery by vitamin E is unclear. As
blood flow in response to NTG was similar at the end of all
periods and comparable to blood flow at baseline, the improve-
ment of NMD under combination therapy cannot be explained
by altered shear stress.
If an antioxidant effect of vitamin E is assumed, our findings
of an improvement in NMD are supported by a study of Galle
et al. (44) who revealed an inhibition of cyclic adenosine
monophosphate- and cyclic guanosine monophosphate-
mediated vasodilation in isolated deendothelialized human
mammary and rabbit femoral arteries by oxidized LDL. The
authors suggested that oxidized LDL could decrease the
efficacy of endogenous as well as exogenous vasodilators either
by direct inactivation of the dilators or by affecting the signal
cascade in the smooth muscle cells. The concept that oxygen-
derived free radicals inactivate the enzymes involved in the
release of nitric oxide from NTG is also supported by findings
of Watanabe et al. (45,46), who demonstrated that vitamin E as
well as vitamin C prevents the development of nitrate toler-
ance. Furthermore, Rajagopalan et al. (47) demonstrated that
enhanced angiotensin II activity resulted in increased vascular
superoxide production via activation of the membrane associ-
ated nicotinamide-adenine dinucleotide oxidase, which inhibits
the vasodilator effect of NTG-derived nitric oxide.
Study limitations. As we did not compare combined vita-
min E and statin therapy with vitamin E alone, we cannot
exclude that the beneficial effect of vitamin E on endothelial
function is at least partly bound to a concomitant LDL-
lowering therapy. Recent studies, however, support the con-
tention that antioxidants improve vascular function indepen-
dent of their ability to inhibit the oxidation of LDL (48,49).
Data from simple linear regression analyses and multiple
stepwise regression analyses need to be interpreted with
caution as measurements were repeatedly performed in the
same patients. However, additional influences on vasodilation
by gender, age and body mass index can be widely excluded as
only men at similar age (51 6 10 yr) were enrolled in the study
and body mass index did not influence FMD as well as NMD
in previous studies (27).
Conclusions. The combination of vitamin E supplementa-
tion and lipid-lowering therapy leads to a marked improve-
ment of endothelial function of the brachial artery within 8
weeks. As previously shown in the coronary circulation, the
combination of antioxidant and lipid-lowering therapy is more
effective than lipid-lowering therapy alone, underscoring the
potential utility of noninvasive testing of peripheral endothelial
function as a surrogate for the coronary artery. The improve-
ment of endothelium-independent vasodilation was an unex-
pected finding which, due to the small number of patients,
requires further investigation.
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